Literature DB >> 2635056

Effects of interleukin-6 on the growth of normal and transformed rat liver cells in culture.

A C Huggett1, C P Ford, S S Thorgeirsson.   

Abstract

Recombinant human interleukin-6 produced a dose-dependent inhibition of DNA synthesis in both growing and mitogen-stimulated cultures of normal rat liver epithelial cells and also in primary rat hepatocytes. A significant inhibition of DNA synthesis (P less than 0.001) was obtained with 1 ng/ml (10 Units/ml) interleukin-6 in normal rat liver epithelial cells. The ID50 for inhibition of DNA synthesis in primary rat hepatocytes was 1 ng/ml. In contrast to the effects of transforming growth factor beta (Type I), where an almost complete inhibition of DNA synthesis could be achieved with either cell type, the maximal inhibition observed with interleukin-6 for both of these cell types was about 45%. Thus distinct mechanisms are involved in the inhibition of liver cell growth by these growth modulators. Transformed liver-derived cell lines were relatively resistant to the growth inhibitory effects of both interleukin-6 and TGF-beta 1 compared with the normal cells. However, human Hep G2 cells, which were completely resistant to the growth inhibitory effects of TGF-beta 1, were moderately inhibited by interleukin-6, indicating that the mechanisms responsible for the acquired resistance to growth inhibition is different for these growth inhibitors. The ability of interleukin-6 to function as a growth inhibitor in vitro was confirmed using normal rat liver epithelial cells. Interleukin-6 at a concentration of 10 ng/ml produced a significant decrease (P less than 0.05) in the proliferation of these cells. These data demonstrate that interleukin-6 may have the capability of functioning as a growth regulatory polypeptide for liver cells in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2635056     DOI: 10.3109/08977198909069084

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  4 in total

1.  Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis.

Authors:  Weici Zhang; Masanobu Tsuda; Guo-Xiang Yang; Koichi Tsuneyama; Guanghua Rong; William M Ridgway; Aftab A Ansari; Richard A Flavell; Ross L Coppel; Zhe-Xiong Lian; M Eric Gershwin
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

2.  Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis.

Authors:  K D Sekiyama; M Yoshiba; A W Thomson
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

3.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.

Authors:  T Ezure; T Sakamoto; H Tsuji; J G Lunz; N Murase; J J Fung; A J Demetris
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  Elevated expression of interleukins in lung adenocarcinomas induced by N-Nitrosobis(2-hydroxypropyl)amine in rats.

Authors:  T Tsujiuchi; Y Sasaki; M Tsutsumi; Y Konishi
Journal:  Jpn J Cancer Res       Date:  2000-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.